Thursday, September 14, 2017 2:44:30 PM
I think this is what you are looking for....
Under the terms of the purchase agreement, dated May 18, 2017, Aurora will pay a consideration to holders of Class B securities of Pedanios approximately 3,421,756 common shares of Aurora, priced at $2.14 per share. In addition, a total consideration of approximately $13,565,000 in cash and common shares is payable to the holders of Class A common shares of Pedanios, which are held by the two founders/Managing Directors of Pedanios who will continue to run the company. The cash portion for the two founders being $3,020,000 and the share portion being 4,895,026 common shares of Aurora, priced at $2.14 per share, of which 17% will become free trading 4 months after closing, with the balance becoming unrestricted in equal installments on a quarterly basis over 27 months, commencing in February 2018. Total shares of Aurora being issued over 3 years represent less than 2% of total shares outstanding. Aurora's cash balance as of May 15, 2017 was $165,000,000. Values herein have been calculated based on an exchange rate of 1.51 Canadian dollars to every 1 Euros.
It is from this news release on May 26, 2017 regarding the acquisition of Pedanios.
http://www.newswire.ca/news-releases/aurora-acquires-german-medical-cannabis-market-leader-pedanios-gmbh-624649463.html
Under the terms of the purchase agreement, dated May 18, 2017, Aurora will pay a consideration to holders of Class B securities of Pedanios approximately 3,421,756 common shares of Aurora, priced at $2.14 per share. In addition, a total consideration of approximately $13,565,000 in cash and common shares is payable to the holders of Class A common shares of Pedanios, which are held by the two founders/Managing Directors of Pedanios who will continue to run the company. The cash portion for the two founders being $3,020,000 and the share portion being 4,895,026 common shares of Aurora, priced at $2.14 per share, of which 17% will become free trading 4 months after closing, with the balance becoming unrestricted in equal installments on a quarterly basis over 27 months, commencing in February 2018. Total shares of Aurora being issued over 3 years represent less than 2% of total shares outstanding. Aurora's cash balance as of May 15, 2017 was $165,000,000. Values herein have been calculated based on an exchange rate of 1.51 Canadian dollars to every 1 Euros.
It is from this news release on May 26, 2017 regarding the acquisition of Pedanios.
http://www.newswire.ca/news-releases/aurora-acquires-german-medical-cannabis-market-leader-pedanios-gmbh-624649463.html
Recent ACB News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 11:29:57 AM
- Aurora Recognized for Executive Gender Diversity by the Globe & Mail for Second Consecutive Year • PR Newswire (US) • 03/30/2026 11:03:00 AM
- Aurora Recognized for Executive Gender Diversity by the Globe & Mail for Second Consecutive Year • PR Newswire (Canada) • 03/30/2026 11:03:00 AM
- Aurora to Participate in the TD Cowen 46th Annual Health Care Conference • PR Newswire (US) • 02/17/2026 11:39:00 PM
- Aurora to Participate in the TD Cowen 46th Annual Health Care Conference • PR Newswire (Canada) • 02/17/2026 11:39:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/12/2026 09:26:03 PM
- Aurora to Ring the Nasdaq Closing Bell on Wednesday, February 18, 2026, Reinforcing Strategic Focus on Global Medical Cannabis • PR Newswire (US) • 02/12/2026 09:05:00 PM
- Aurora to Ring the Nasdaq Closing Bell on Wednesday, February 18, 2026, Reinforcing Strategic Focus on Global Medical Cannabis • PR Newswire (Canada) • 02/12/2026 09:05:00 PM
- Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand • PR Newswire (US) • 02/11/2026 12:00:00 PM
- Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand • PR Newswire (Canada) • 02/11/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/04/2026 09:44:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/04/2026 02:45:22 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/04/2026 12:27:19 PM
- Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] • Edgar (US Regulatory) • 02/04/2026 12:10:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/04/2026 12:05:38 PM
- Aurora Cannabis Announces Fiscal 2026 Third Quarter Results • PR Newswire (Canada) • 02/04/2026 12:00:00 PM
- Aurora Cannabis Announces Fiscal 2026 Third Quarter Results • PR Newswire (US) • 02/04/2026 12:00:00 PM
- Aurora Cannabis Announces Filing of Prospectus Supplement for At-The-Market Offering Program • PR Newswire (US) • 02/04/2026 12:00:00 PM
- Aurora Cannabis Announces Filing of Prospectus Supplement for At-The-Market Offering Program • PR Newswire (Canada) • 02/04/2026 12:00:00 PM
- Aurora Launches New European Websites, Showcasing Science-Backed Cannabis Leadership • PR Newswire (US) • 02/03/2026 12:00:00 PM
- Aurora Launches New European Websites, Showcasing Science-Backed Cannabis Leadership • PR Newswire (Canada) • 02/03/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/21/2026 10:17:54 PM
- Aurora Cannabis to Host Third Quarter 2026 Investor Conference Call • PR Newswire (Canada) • 01/21/2026 09:35:00 PM
- Aurora Secures EU Community Plant Variety Rights for Two Proprietary Cannabis Varieties • PR Newswire (US) • 01/20/2026 12:00:00 PM
- Aurora Secures EU Community Plant Variety Rights for Two Proprietary Cannabis Varieties • PR Newswire (Canada) • 01/20/2026 12:00:00 PM
